Hengrui Pharma Reports Steady Growth in Q3 2025 Driven by Innovation and Global Expansion

By SquaredTown on October 27, 2025

SHANGHAI, Oct. 27, 2025 /PRNewswire/ -- Hengrui Pharma (600276.SH; 01276.HK) reported revenue of RMB23.20 billion for the first three quarters of 2025, up 14.85% year-on-year. Net profit attributable to shareholders was RMB5.75 billion, increased by 24.50% compared with the same period...

Read More